Skip to main content

Read an important notice regarding the data security incident McKesson reported on August 28, 2026. Read more.

Clinical Trials

BRCC Research Institute 2026

< All Clinical Trials

GDC-6036 in combination w/other anti-cancer therapies in untreated metastatic NSCLC w/KRAS G12C mut

Disease Type: Lung

A Phase Ib/II, open-label, multicenter study evaluating the safety, activity, and pharmacokinetics of GDC-6036 in combination with other anti-cancer therapies in patients with previously untreated advanced or metastatic non-small cell lung cancer with a KRAS G12C mutation

Locations

Alleghany , Blacksburg , Roanoke , Salem , Wytheville

View on ClinicalTrials.gov